Tag Archive for: Phase IIb

Leuven-based Augustine Therapeutics NV will use the proceeds from a €77.7m in Series A financing led by Novo Holdings and Jeito Capital to advance its preclinical HDAC6 inhibitor AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease to Phase I testing.

Following the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.